Tylenol v. Advil: who'll come out on top?

Johnson & Johnson said it's returning some versions of children's and infant's Tylenol to stores after recalling millions of bottles earlier this year. How the brand fares may depend on the degree to which it can hold onto consumer loyalty.
Researchers from The Relational Capital Group and Princeton University surveyed 1,042 US consumers and found that the Tylenol brand slightly outpaces Pfizer's Advil in consumer loyalty (67% vs. 65% positive) and purchase intent (76% vs. 75% positive).

Respondents rated both brands equally well on such statements “is honest and trustworthy” and “acts with your best interest in mind.” These dimensions were shown to impact purchase intent and loyalty.  

Chris Malone, chief advisory officer of The Relational Capital Group, said consumers have interpreted J&J's quality control problems as “a temporary lapse in competence.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.